Neuropace/$NPCE
1D1W1MYTD1Y5YMAX
Capital at risk
About Neuropace
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
- Ticker
- $NPCE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 220
- Headquarters
- Mountain View, United States
- Website
- www.neuropace.com
Neuropace Metrics
BasicAdvanced
$482M
-
-$0.57
1.94
-
Price and volume
Market cap
$482M
Beta
1.94
52-week high
$19.60
52-week low
$9.22
Average daily volume
181K
Financial strength
Current ratio
4.944
Quick ratio
3.822
Long term debt to equity
569.511
Total debt to equity
588.496
Interest coverage (TTM)
-1.92%
Profitability
EBITDA (TTM)
-11.877
Gross margin (TTM)
77.38%
Net profit margin (TTM)
-17.86%
Operating margin (TTM)
-11.34%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-7.47%
Return on equity (TTM)
-103.27%
Valuation
Price to revenue (TTM)
4.408
Price to book
40.51
Price to tangible book (TTM)
40.51
Price to free cash flow (TTM)
-40.621
Free cash flow yield (TTM)
-2.46%
Free cash flow per share (TTM)
-0.346
Growth
Revenue change (TTM)
33.16%
Earnings per share change (TTM)
-32.16%
3-year revenue growth (CAGR)
24.89%
3-year earnings per share growth (CAGR)
-30.50%
What the Analysts think about Neuropace
Analyst ratings (Buy, Hold, Sell) for Neuropace stock.
Analyst projections of the future price of Neuropace stock.
Bulls say / Bears say
NeuroPace reported first quarter 2026 revenue of $22.1 million, up 20.1% year-over-year, beating expectations and prompting management to raise its full-year guidance to $99 million–$101 million. (Reuters)
In the fourth quarter of 2025, revenue grew 24% year-over-year to $26.59 million, driven by a 26% increase in RNS System sales and improved gross margins from favorable product mix and manufacturing efficiencies. (Reuters)
Preliminary one-year data from the NAUTILUS IDE trial showed the RNS System met its 12-week post-implant safety endpoint and delivered favorable seizure reduction rates in treated patients. (Reuters)
The NAUTILUS trial failed to achieve its primary efficacy endpoint in the overall population, raising questions about the RNS System’s effectiveness across broader epilepsy indications. (Reuters)
On July 28, 2026, NeuroPace disclosed in an SEC filing that the FDA deemed its PMA supplement for expanding the RNS System into idiopathic generalized epilepsy not approvable in its current form, requesting additional clinical evidence and delaying regulatory progress. (SEC 8-K)
The company continues to operate at a loss, reporting a GAAP net loss of $6.7 million in the first quarter of 2026, roughly unchanged from $6.6 million in the prior-year period, underscoring a protracted path to profitability. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
Neuropace Financial Performance
Revenues and expenses
Neuropace Earnings Performance
Company profitability
Upcoming events
No upcoming events
Neuropace News
AllArticlesVideos
Funds containing Neuropace
AllGBPEUR
Fund name | Fund size | $NPCE weighting |
|---|---|---|
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.